OKYO Pharma Ltd ADR

Yahoo Finance • 25 days ago

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for infla... Full story

Yahoo Finance • 3 months ago

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflam... Full story

Yahoo Finance • 3 months ago

OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering

OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering Proactive uses images sourced from Shutterstock OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic cor... Full story

Yahoo Finance • 5 months ago

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition ass... Full story

Yahoo Finance • 5 months ago

Nutex Health Soars 21% After Hours On Revenue Surge; Biotech Peers Join Tuesday Gainers

(RTTNews) - Several small-cap biotech and pharma names posted notable gains in Tuesday's after-hours trading session, with Nutex Health standing out as the most significant mover following its quarterly results. Nutex Health Inc. (NUTX) s... Full story

Yahoo Finance • 7 months ago

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition as... Full story

Yahoo Finance • 10 months ago

OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $7.00 price target on OKYO Pharma Ltd. (NASDAQ:OKYO), representing a 136% upside from the current price of $2.96, following positive Phase 2 trial results for its neuropathic... Full story

Yahoo Finance • 10 months ago

OKYO Pharma reports results from Urcosimod trial

[Light beam is shining through retina and lens on eyesight exam] Zorica Nastasic/E+ via Getty Images * OKYO Pharma (NASDAQ:OKYO [https://seekingalpha.com/symbol/OKYO]) shared positive results from a recent mid-stage study that tested Ur... Full story

Yahoo Finance • 10 months ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.U... Full story

Yahoo Finance • last year

OKYO Pharma Announces Chairman and CEO Acquire Shares

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular co... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.Second clinical indication for OK-101 wh... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")

Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial.The dropout rate is... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to addres... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial, with pre-specified primary efficacy endp... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule

NEW YORK and LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address... Full story

Yahoo Finance • 3 years ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

LONDON and NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet n... Full story